Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analysis reveals a role for PAX8 in high grade serous ovarian cancer metastasis that can be targeted with micelle encapsulated thiostrepton

ABSTRACT: We used proteomic and transcriptomic analysis to examine the role of PAX8 leading to increased migratory capabilities in a human ovarian cancer model as well as in tumor models derived from the OSE and FTE.

INSTRUMENT(S): Agilent 6550 QTOF, QExactive Classic

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) Mus Musculus (ncbitaxon:10090)

SUBMITTER: Stephanie Cologna

PROVIDER: MSV000083585 | MassIVE | Sun Mar 17 10:29:00 GMT 2019

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

LncRNA and mRNA expression profiles in High-grade serous ovarian cancer, Low-grade serous ovarian cancer and Normal fallopian tube

Project description:Ovarian cancer is the most lethal gynecologic cancer. High-grade serous ovarian carcinoma (HGSOC) is the most common histologic subtype, accounting for three quarters of ovarian cancer. To clarify the changes of gene expression in serous ovarian cancer, we performed lncRNA and mRNA microarrays to identify differentially expressed lncRNAs and mRNAs in High-grade and Low-grade serous ovarian carcinoma compared with Normal fallopian tube.

2020-02-12 | GSE135886 | GEO

Platinum chemotherapy induces diverse evolutionary trajectories in high grade serous ovarian cancer

Project description:Cisplatin- and carboplatin-resistant high-grade serous ovarian cancer (HGSC) cells were generated and new lines were created from single cell clones. All cells were derived from a common ancestral line, Ovcar4. RNA sequencing was performed to examine transcriptional changes related to acquisition of platinum resistance.

2022-08-01 | GSE141630 | GEO

Gene count level transcriptomic data of high grade serous ovarian cancer

Project description:Transcriptomic profiling was done on 81 primary tumours, 1 relapse tumour, 5 autopsy tumours (whole tissue sections or macrodissected to enrich for tumour), 29 ascites and 7 normal fallopian tube samples. 1 of the primary tumours is a low grade serous ovarian cancer sample.

2022-08-02 | GSE209964 | GEO

miRNA profiling in high-grade serous ovarian carcinoma

Project description:In this study, we performed miRNA profiles analysis of high-grade serous ovarian carcinoma compared to normal fallopian tube fimbria using microarray (Exiqon, Denmark) to evaluate their potential role in the pathogenesis of uterine leiomyoma. miRNA profiling analysis of the 10 samples including 5 high-grade serous ovarian carcinomas and 5 normal fallopian tube fimbria.

2014-11-14 | E-GEOD-61485 | biostudies-arrayexpress

Can High Grade Serous Ovarian Cancer TCGA Gene Expression Signatures be seen in High Grade Endometrioid or Clear Cell Ovarian Cancer?

Project description:The goal of the study was to examine the transcriptional profile of ovarian cancer cancers in order to develop validated clinically useful prognostic signatures with the potential to guide therapy decisions. Fresh frozen samples were prospectively collected from a series of 107 consecutive women with high-grade serous ovarian, primary peritonial, or fallopian tube cancer as well as high grade clear cell and endometrioid cancer who underwent surgery by a gynecologic oncologist at Mayo Clinic between 1994 and 2005. All patients received postoperative chemotherapy with a platinum agent, and 75% received a taxane. All patients signed an Institutional Review Board approved consent for bio-banking, clinical data extraction and molecular analysis. Median follow-up time was 35 months (range, 1-202 months). Fourteen patients (8%) were included in the TCGA study.

2015-10-01 | GSE73614 | GEO

Ovarian high grade serous carcinoma ascites cell proteoms

Project description:Tumor cells, macrophages and T cells from high grade serous ovarian carcinoma from the ascites of patients undergoing primary surgery were analysed without culturing (ex vivo) via obitrap.

2017-11-17 | PXD006138 | Pride

Ovarian high grade serous carcinoma ascites cell secretome

Project description:The secretomes of tumor cells, and macrophages from high grade serous ovarian carcinoma from the ascites of patients undergoing primary surgery were analysed after 24h culture (ex vivo) via obitrap.

2017-11-17 | PXD008047 | Pride

Genomic analysis of low-grade serous ovarian carcinomas [IL610Q]

Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes between co-existing borderline and invasive components of serous carcinoma. Paired co-existing borderline and invasive tumor components of ovarian serous carcinoma were sampled and profiled from tumors from 7 patients

2014-10-01 | E-GEOD-57279 | biostudies-arrayexpress

Genomic analysis of low-grade serous ovarian carcinomas [EXP]

Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differentially expressed genes between co-existing borderline and invasive components of serous carcinoma.

2014-10-01 | GSE56443 | GEO

Genomic analysis of low-grade serous ovarian carcinomas [ILOE]

Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes in borderline and invasive components of serous carcinoma.

2014-10-01 | GSE57270 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data